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Impaired autoregulation of GFR in hypertensive non-insulin
dependent diabetic patients
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Impaired autoregulation of GFR in hypertensive non-insulin dependent
diabetic patients. We investigated the effect of acute lowering of blood
pressure (BP) upon glomerular filtration rate (GFR) in hypertensive
non-insulin-dependent diabetes mellitus (NIDDM) patients, 14 with
diabetic nephropathy and 12 with normoalbuminuria. The study was
performed twice with the subjects receiving an intravenous injection of
either clonidine (150 to 225 rg) or saline (0.154 mmol/liter). We assessed
GFR, albuminuria, and BP. The two groups were well matched with
respect to demographic data, baseline GFR and BP. Clonidine induced
similar reductions in mean arterial blood pressure 19 (SE 4) and 21 (SE
3) mm Hg in patients with and without nephropathy, respectively. In the
nephropathy group GFR diminished in average from 90 (se 6) to 81
(SE 7) ml/min/1.73 m2 (P = 0.006), fractional clearance of albumin
(X 10—6) declined from a geometric mean of 219 (antilog SE I÷ 1.3) to 186
(antilog SE 1.3) (P = 0.04), and four patients had a complete
pressure-passive vasculature, defined as GFR% = MABP%. A signif-
icant correlation between relative reductions in MABP and GFR (r =
0.78, P < 0.001) was demonstrated in albuminuric patients. None of the
normoalbuminuric patients had a complete pressure-passive vasculature
and there were no significant differences in GFR between the two
examinations, but five had abnormal autoregulation of GFR. Mean
difference between changes in GFR (95% confidence interval) between
the nephropathic and normoalbuminuric group was 5.5 (-i- 2.7 to 13.7)
ml/min/i.73 m2 (P = 0.18). Our study suggests that hypertensive NIDDM
patients, particularly patients with nephropathy, frequently suffer from
impaired or abolished autoregulation of GFR.
Initiation of antihypertensive treatment induces a faster initial
and slower subsequent decline in glomerular filtration rate (GFR)
in hypertensive insulin-dependent diabetes mellitus (IDDM) and
non-insulin-dependent diabetes mellitus (NIDDM) patients with
incipient or overt diabetic nephropathy [1—3]. The faster initial
decline in GFR may be due to a functional (hemodynamic) effect
of antihypertensive treatment in patients with diabetic nephro-
pathy [4, 5]. Furthermore, studies suggest that the normal auto-
regulation in GFR, that is, the maintenance of GFR within
normal limits during changes in perfusion pressure induced by
changing arterial blood pressure (BP), is defective in IDDM
patients with diabetic nephropathy [6]. No information on this
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important servo mechanism is available in hypertensive NIDDM
patients with diabetic nephropathy.
Therefore, the aim of our study was to investigate the effect of
acute blood pressure reduction upon GFR in hypertensive
NIDDM patients with diabetic nephropathy.
METHODS
All 131 NIDDM patients with diabetic nephropathy (biopsy
verified N = 28, or clinical criteria N = 103) attending the
outpatients clinic at Steno Diabetes Center during 1995 were
identified. Diabetic nephropathy was diagnosed clinically if the
following criteria were fulfilled: persistent albuminuria (> 300
mg/24 hr in at least two out of three consecutive, sterile, nonke-
totic, 24-hour urine samples), presence of diabetic retinopathy,
and no clinical or laboratory evidence of other kidney or renal
tract disease [7]. The patients were considered to have NIDDM if
they fulfilled the WHO definition of NIDDM [8].
Inclusion criteria were the following: NIDDM with diabetic
nephropathy, age at entry  18 and  70 years, and GFR  25
ml/min/173 m2. One-hundred and five patients were excluded
because of the following reasons: age > 70 years (N = 24),
GFR < 25 ml/min/173 m2 (N = 8), treatment with more than two
antihypertensive drugs or systolic blood pressure > 190 mm Hg
despite treatment with two antihypertensive drugs (N = 32),
severe cardiovascular disease (N = 29), blindness (N = 4),
superimposed non-diabetic kidney disease (N = 3), cancer (N =
1), mental disease (N = 4). Twenty-six patients were eligible for
the study, 9 were unwilling to participate, 3 patients dropped out
after inclusion. Fourteen hypertensive (repeated office BP record-
ing > 140/90 mm Hg) patients with NIDDM and diabetic
nephropathy (N = 4 with biopsy-verified diabetic glomeruloscle-
rosis) completed the study.
All NIDDM patients without known diabetic nephropathy
(N = 817) attending the outpatients clinic at Steno Diabetes
Center during 1995 were identified. Three hundred and fifty-six
patients had normoalbuminuria. Thirty-six hypertensive NIDDM
patients with normoalbuminuria (albuminuria < 30 mg/24 hr)
were eligible for the study, since they matched the NIDDM
patients with diabetic nephropathy with respect to sex, age and
arterial blood pressure level. Twenty were unwilling to participate
and four patients dropped out after inclusion. Twelve hyperten-
sive patients with NIDDM and normoalbuminuria completed the
study. Four weeks before the first examination, all antihyperten-
sive treatment was withdrawn in both patients groups, but two
patients in each group received furosemide (40 to 80 mg/day)
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because of edema formation. All subjects included in the study
gave informed consent to participate in the study. The study was
approved by the local ethics committee and conducted according
to the principles expressed in the Declaration of Helsinki.
We performed a randomized single-blind crossover study. The
study was performed twice within two weeks, with the subjects
receiving a slow intravenous injection (10 mm) at 8:20 a.m. of
either clonidine (150 to 225 jig; Boehringer, Ingeiheim, Germany)
or saline (0.154 mmol/liter), in random order. The patients had
their normal breakfast and antidiabetic treatment.
The GFR was measured in a four hour period after a single
intravenous injection of 3.7 MBq of Na 51Cr-labeled edetic acid
([51Cr] EDTA) at 8.30 a.m., by determining the radioactivity in
venous blood samples taken at 180, 200, 220, and 240 minutes
after the injection [9, 10]. The small underestimation (10%) of
51Cr EDTA clearance versus clearance of inulin was corrected for
by multiplying EDTA clearance by 1.10 [9]. The results were
standardized for 1.73 m2 body surface area, using the patients'
surface area at the start of the study. The mean coefficient of
variation in GFR rate of each patient from day to day was 4%.
Patients rested supine during the entire investigation and drank
approximately 200 ml of tap water per hour.
Blood pressure and heart rate was measured with the Takeda
TM2420 device (A&D, Tokyo, Japan) using right arm, appropri-
ate cuff sizes [25 X 12 cm (upper arm circumference 35 cm) and
30 >< 15 cm (upper arm circumference > 35 cm)] at baseline after
at least 10 minutes rest in the supine position (average of 3
measurements) at 8.10 a.m. and every 10 minutes during the GFR
measurements. Mean arterial blood pressure (MABP) was calcu-
lated as diastolic blood pressure plus one third of the pulse
amplitude.
Blood glucose concentration was measured every hour during
the four hour period by a glucose-oxidase method on an autoana-
lyzer (one touch 2; Lifescan, Milpitas, CA, USA).
Urinary albumin excretion (UAE) during the four hour period
was determined by using an enzyme-linked immunoadsorbent
assay, intra-assay variation 2.1% and interassay variation 8.3%
[11]. Fractional clearance of albumin was obtained by dividing the
clearance of albumin (calculated as UV/P, where U is urine
albumin concentration, V is urine flow, and P is plasma albumin
concentration) with the simultaneously measured GFR. Residual
urine was determined by an ultrasonic diagnosis apparatus
(Toshiba Sonolayergraph SAL-20A; Tokyo Shibaura Electric Co.,
Ltd., Tokyo, Japan). Urinary sodium excretion was measured
during the four-hour GFR measurement. Morning urine was
tested for bladder infection by a stix (Nephur-Test; Boehringer
Mannheim, Mannheim, Germany).
Hemoglobin A1 (HbA1) was measured by high performance
liquid chromatography (VARIANT analyzer; BlO-RAD, CA,
USA). The normal range of HbAIC in our laboratory is 4.1 to
6.4%.
Statistical analysis
Normally distributed data are expressed as mean and SD or SE.
Values for albuminuria and fractional albumin clearance were
logarithmically transformed and expressed as geometric mean and
antilog SE, because of their positively skewed distribution. All
comparisons of normally distributed parameters were done with a
Student's t-test, and intergroup comparisons were done with
unpaired and intragroup comparisons using paired design. Wil-
coxon's non-parametric test for paired comparison was used for
analysis of urinary albumin excretion. All blood pressure measure-
ments during the four hour period were used to calculate the
mean values and SD during each examination in each patient. The
differences between the two examination was transformed into
relative changes and linear regression analysis was used to analyze
for correlations between relative change in MABP (%) and
relative change in GFR (%) in patients with and without nephrop-
athy. Spearman rho was estimated for the correlations between
change in MABP and changes in albuminuria and fractional
clearance of albumin. All calculations were made using SPSS for
Windows (SPSS Inc., Chicago, IL, USA). A P value of < 0.05 was
considered significant (two-tailed).
RESULTS
The two groups were well matched regarding arterial blood
pressure, age, sex, and body mass index (BMI). Patients with
nephropathy had a significantly higher HbA1C and a longer known
duration of diabetes. All patients in both groups had hypertension
defined as repeated arterial blood pressure> 140/90 mm Hg. Two
patients with nephropathy versus 5 without nephropathy had
never received antihypertensive treatment (Table 1). Intravenous
clonidine injection induced an equal and significantly reduction in
MABP of 19 mm Hg and 21 mm Hg in patients with and without
nephropathy, respectively (P < 0.001). MABP was not reduced
below 80 mm Hg in any patients. Arterial blood pressure reduc-
tion for each patient are shown in Table 2 and Figure 1,
demonstrating a more variable BP response in patients with
nephropathy.
Twelve out of 14 patients with nephropathy had a reduction in
GFR (mean difference 9 mI/mm per 1.73 m2; P =0.006) versus
the control group where only 7 out of 12 patients had a reduction
(mean difference 4 mI/mm per 1.73 m2; NS) after clonidine
injection. Mean difference between changes in GFR (95% confi-
dence interval) between the nephropathic and normoalbuminuric
patients group was 5.5 (± 2.7 to 13.7) ml/min/1.73 m2, P = 0.18.
Their was no significant difference in GFR (mI/mm per 1.73 m2)
before clonidine injection between the two groups (90 23 in the
nephropathy group vs. 93 15 in the control group; NS; Table 2).
Ten out of 14 patients with nephropathy had a reduction in
albuminuria (P < 0.05) and in fractional clearance of albumin
(P < 0.05) as shown in Table 2. A significant correlation between
the reduction in MABP and the reduction in albuminuria (rho =
0.55, P = 0.04) as well as fractional clearance of albumin (rho =
0.55, P = 0.04) was demonstrated in patients with diabetic
nephropathy.
We found a significant correlation between the percent of
relative change in MABP and relative change in GFR (r = 0.78,
P < 0.001) in patients with nephropathy, while no correlation was
found in the control group (r = 0.41, P = 0.19; Fig. 1). Four
patients with nephropathy had a nearly equal relative change in
MABP and GFR (Fig. 1). In the control group no patients had a
complete pressure-passive vasculature, but 5 out of the 12 patients
investigated had an abnormal autoregulation of GFR, that is, >
10% reduction in relative GFR.
No correlation was found between the autoregulation index
[relative change in GFR (%)/relative change in MABP (%)] and
baseline albuminuria or GFR in any of the groups.
Intravenous clonidine injection induced a significant mean
reduction in natriuresis in the albuminuric and normoalbuminuric
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Table 1. Clinical data of NIDDM patients with and without diabetic nephropathy
Age BMI
Subjects Sex years kg/rn2
Known duration
of diabetes
years
HbA1C
%
Baseline BP
mm Hg
Previous
antihypertensiv
treatment
Antidiabetic
treatment
Diabetic
retinopathy
NIDDM patients with diabetic nephropathy
1 M 47 28 8 10.0 142/86 Nil Tablet Nil
2 M 66 26 18 9.5 163/76 Yes Tablet Proliferativ
3 M 63 33 4 8.4 146/84 Yes Tablet Proliferativ
4 M 63 25 25 9.5 192/97 Yes Insulin Simplex
5 M 63 35 21 7.8 155/81 Yes Tablet Simplex
6 M 59 31 34 9.7 152/89 Yes Insulin Proliferativ
7 M 69 32 27 9.1 167/91 Yes Insulin Proliferativ
8 M 66 26 9 8.1 185/75 Yes Insulin Nil
9 F 42 26 9 5.5 144/77 Nil Insulin Proliferativ
10 F 46 34 16 11.0 172/86 Yes Insulin Simplex
11 M 63 26 6 7.2 184/71 Yes Tablet Nil
12 M 68 31 21 11.1 177/96 Yes Insulin Proliferativ
13 M 46 38 11 12.2 148/88 Yes Insulin Simplex
14 M 42 33 1 7.3 163/99 Yes Tablet Nil
Mean so 57 10 30 4 15 10 9 2 164/85 17/9
NIDDM patients with normoalbuminuria
M 50 29 1 7.4 144/91 Nil Diet alone Nil
2 M 66 24 10 6.9 174/1 05 Nil Insulin Nil
3 M 66 34 10 7.2 148/76 Yes Tablet Simplex
4 M 61 31 12 7.5 186/79 Yes Insulin Simplex
5 M 68 27 6 9.4 162/98 Nil Tablet Nil
6 M 63 33 4 7.2 192/87 Yes Insulin Simplex
7 F 56 32 11 7.5 151/89 Yes Insulin Proliferativ
8 F 65 40 10 6.7 200/109 Yes Tablet Simplex
9 M 62 31 20 8.6 166/88 Yes Insulin Proliferativ
10 M 69 20 11 7.7 156/85 Nil Insulin Simplex
11 M 55 28 6 7.9 164/92 Yes Insulin Simplex
12 M 60 36 1 7.1 156/104 Nil Diet alone Nil
Mean so 62 6 30 5 8 5 7.6 1 167/92 19/10
P value NS NS = 0.048 0.016 NS
(intergroup comparisons)
groups, 4.7 (95% confidence interval, 0.2 to 9.1) mmol/hr, P =
0.04, and 8.1 (1.5 to 14.7) mmol/hr, P = 0.02, respectively. The
mean difference between the changes in natriuresis (95% confi-
dence interval) in the ncphropathic and the normoalbuminuric
groups was —3.4 (—10.7 to 3.9) mmol/liter, NS.
No patients had blood glucose concentration below 3 mmol/
liter (average of 5 measurements) during the four-hour clearance
period. There were no significant difference in blood glucose
concentration (mmol/liter) between the two groups during the two
examinations: 7.8 2.9 versus 9.2 3.8, NS (before and after
clonidine injection), and 6.4 1.6 versus 7.4 1.7, P = 0.022
(before and after clonidine injection) in patients with and without
nephropathy, respectively. There were no significant correlations
between blood glucose changes and GFR changes. Furthermore,
the response of patients receiving insulin treatment did not differ
from those on tablets.
Apart from a dry mouth and sleepiness, no serious side-effects
were observed after clonidine injection.
DISCUSSION
Our randomized single-blinded crossover study shows that
acute lowering of BP following intravenous injection of clonidine
reduces GFR, albumiriuria, and fractional clearance of albumin in
hypertensive NIDDM patients with diabetic nephropathy. It
should be mentioned that a wide variation in responses to acute
blood pressure reduction (ranging from normal to severely im-
paired autoregulation) was demonstrated, despite that no patients
had a MABP below the lower normal limit of autoregulation that
is, 80 mm Hg [12—161. A complete pressure-passive vasculature
was found in 4 out of 14 patients with nephropathy [MABP (%)
= z GFR (%)]. In the control group no patients had complete
pressure-passive vasculature and there were no significant differ-
ence in GFR between the two examinations; however, 5 out of the
12 patients investigated had an abnormal autoregulation of GFR,
that is,> 10% reduction in relative GFR. A significant correlation
between z MABP (%) and GFR (%) was demonstrated in
patients with nephropathy, while this correlation was insignificant
in the control group. The two groups had nearly the same BP
before intravenous injection of clonidine and equal average
reduction in blood pressure after intravenous injection of
clonidine.
Omitting the two patients in each group receiving a small dose
of furosemide did not alter the observed differences within and
between the two groups. This is in agreement with previous
studies reporting that autoregulation of renal blood flow and GFR
are maintained after administration of loop diuretics [17, 18].
There was no significant difference in blood glucose concentra-
tion during the renal clearance studies between the two groups.
Furthermore, a glycemic effect on GFR and albuminuria is
lacking in diabetic nephropathy [19, 20]. Thus, it seems highly
unlikely that the present small difference in metabolic control had
any impact on the measured kidney function variables.
Since for safety reasons we excluded hypertensive proteinuric
NIDDM patients with severe vascular and hemodynamic abnor-
malities, the present study may well underestimate the acute
impact of blood pressure reduction on kidney function.
We have used the plasma clearance of 51Cr-EDTA for GFR
determination during the last 25 years, because this method is
accurate, precise (coefficient of variation 4%), and does not
require frequent timed urine collections as do classical renal
clearance procedures 9, 10]. The coefficient of variation for renal
clearance of 5tCr-EDTA, calculated from four urine collection
periods of 40 minutes each, was as high as 20% in patients with
diabetic nephropathy [21]. This is mainly due to residual urine
that is frequently found in long-standing diabetic patients due to
diabetic cystopathy [22]. We have demonstrated that correction
for residual urine reduces the coefficient of variation in renal
clearance in NIDDM patients from 23% to 6% [23]. Finally,
subjects receiving intravenous clonidine cannot stand up and void
for four to five hours because of an orthostatic blood pressure
drop.
Originally, we reported defective GFR autoregulation in
IDDM patients with diabetic nephropathy using clonidine as a
blood pressure lowering drug [61. Our reasons for selecting
clonidine as a hypotensive drug, in the past and the present study,
were its lack of direct pharmacological effects on the renal vessels
[24—26], its predictable effectiveness, and its safety in inducing a
prolonged fall in arterial pressure lasting five to seven hours after
intravenous injection. An intravenous bolus injection of clonidine
has a brief direct aipha-adrenergic stimulating effect lasting a few
minutes (hypertension), followed by a prolonged suppression of
the central nervous system sympathetic centers (hypotension) [24,
251. No peripheral sympathetic inhibition has been demonstrated.
In an attempt to avoid the initial rise in blood pressure, we
intravenously injected clonidine slowly (10 mm). Intravenous
injection of clonidine in normo- and hypertensive subjects induces
a slight but insignificant reduction in peripheral and renal vein
renin concentration [24, 26]. The decrease in the blood pressure is
due to diminished cardiac output and not to effects on total
peripheral resistance [25, 26]. Intravenous injection of clonidine
(150 to 300 j.Lg) to normo- and hypertensive nondiabetic subjects
induces no significant change in renal plasma flow and GFR [6,
24, 26]. The average reduction in mean arterial blood pressure
ranged from 17 to 27 mm Hg in the three studies. Since the
relative reduction in GFR did not exceed 10% of the baseline
value, this level was used as the cut off for normal autoregulation.
Autoregulation of GFR, that is, the maintenance of relative
constancy of GFR despite variations in MABP above 80 mm Hg,
is present in innovated, denervated and isolated kidney [16, 27,
281. Experimental studies suggest that autoregulation of GFR is
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Table 2. Blood pressure (BP), glomerular filtration rate (GFR) and urinary albumin excretion (UAE) before and during acute blood pressure
reduction in NIDDM patients with and without diabetic nephropathy
BP mm Hg GFR mi/mm per 1.73 m2
Subject Before clonidin After clonidin Before clonidin After clonidin
UAE p.g/min
Before clonidin After clonidin
98 103 277 286
Fractional clearance of albumin
(x106)
Before clonidin After clonidin
P
71 71
92 65 1391 630 360 255
105 94 178 134 40 37
92 84 2925 1426 1060 566
54 47 280 615 126 319
76 66 2607 2102 1107 910
91 55 1553 495 474 257
98 90 222 177 63 55
77 71 221 276 78 100
54 53 517 455 266 232
112 112 681 626 156 140
62 57 2080 678 932 350
133 125 668 676 136 142
112 106 1457 1026 310 236
90 23 81 25 708 (1.3)a 532 (1.2y 219 (1.3)a 186 (1.3)a
<0.001
NIDDM patients with diabetic nephropathy
1 147/94 7/12 144/85 7/3
2 181/95 12/8 126/71 17/13
3 151/84 11/6 137/80 10/7
4 201/88 13/8 163/78 16/Il
5 154/86 4/3 124/78 11/5
6 176/100 16/5 121/76 15/12
7 192/100 19/11 111/70 29/14
8 203/92 16/10 137/80 20/15
9 149/81 10/4 128/75 17/5
10 166/82 14/5 159/82 8/4
11 185/81 21/7 141/73 11/5
12 176/95 10/10 153/82 10/6
13 159/92 10/6 157/88 9/5
14 152/94 7/3 122/82 8/3
Mean SD 171/90 20/7 138/79 16/5
NIDDM patients with normoalbuminuria
1 148/93 3/3 123/83 5/5
2 165/89 12/12 117/75 13/12 97 87
3 156/81 11/5 120/79 5/4 73 78
4 173/86 12/6 126/77 8/9 96 97
5 171/106 8/4 142/89 7/6 83 75
6 194/99 7/4 144/82 23/12 97 81
7 160/93 9/4 122/82 5/4 107 99
8 189/105 10/6 121/79 12/5 90 77
9 158/86 27/10 121/72 7/3 91 95
10 141/81 6/4 112/70 7/6 106 93 4 11 1.0 3.1
11 149/85 9/6 152/90 9/6 64 65 10 7 4.3 2.9
12 166/107 11/6 121/88 8/6 93 89 306 12 8.3 3.6
Mean SD 164/93 16/10 127/80 12/7 93 15 89 18 8 (1.2)a 6 (1.ly' 2.2 (i.2y 1.8 (1.1
= 0.006 = 0.02 = 0.04
119 136 7 6 1.3 1.1
4 5 1.0 1.4
9 5 2.9 1.5
7 5 1.9 1.4
19 6 6.2 2.4
7 3 1.9 1.0
5 4 1.3 1.1
12 4 3.3 1.3
4 9 1.2 2.6
P < 0.001 NS NS NS
Geometric mean (antilog sa)
h All (N = 4) previous UAE < 30 mg/24 hr during the last 6 months before the study
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to enhanced transmission of the systemic pressure into the
glomerular capillary network, and glomerular hypertension [28,
34]. This hemodynamic alteration is associated with an increase in
proteinuria and acceleration of glomerular sclerosis [27]. Con-
versely, we found a decrease in albuminuria and fractional
clearance of albumin (particularly gross albuminuria) induced by
acute blood pressure reduction, suggesting that albuminuria is
pressure dependent, probably due to diminished glomerular cap-
illary hydrostatic pressure. The impaired myogenic responses to
pressure changes might be caused by arteriolar hyalinosis, which
has been seen in biopsy specimens from kidneys with hypertensive
lesions and/or diabetic glomerulosclerosis [35, 36], or metabolic
disturbance of the preglomerular vessels, or a combination of both
of these factors [32, 331. Furthermore, it has been suggested that
autoregulation of GFR in general could be governed by various
humoral substances, such as prostaglandins and the renin-angio-
tensin system. However, postaglandins synthetase inhibitors and
angiotensin II antagonists failed to interfere with autoregulation
in the majority of studies performed [37, 38].
Regardless of the precise mechanisms for the failure of auto-
10 20 regulation, the clinical significance of impaired autoregulation of
GFR in hypertensive diabetic patients with and without nephrop-
athy is the lack or diminished protection against hyper- or
hypoperfusion induced by alteration in blood pressure. In other/ words, there is increased vulnerability to hypertension or ischemic
injuries of glomerular capillaries in diabetic patients with ne-/ phropathy [39—41]. This finding may in part explain the beneficial
effect of aggressive antihypertensive treatment on progression of
diabetic nephropathy.
Reprint requests to Per Knud Christensen, Steno Diabetes Center, Niels
Steensens Vej 2, DK-2820 Gentofte, Denmark.
E-mail address: pkc@novo.dk.
APPENDIX
Abbreviations used in this article are: BP, blood pressure; GFR,
glomerular filtration rate; NIDDM, non-insulin dependent diabetes mel-
litus; IDDM, insulin dependent diabetes mellitus; UAE, urinary albumin
excretion; MABP, mean arterial blood pressure; HbA1, hemoglobin A;
BMI, body mass index.
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